L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with α-interferon and ribavirin

Digestive Diseases and Sciences

Volumn 53, Issue 4, 2008, Pages 1114-1121

  Romano, Marcello ^a   Vacante, Marco ^a   Cristaldi, Erika ^a   Colonna, Valentina ^a   Gargante, Maria Pia ^a   Cammalleri, Lisa ^a   Malaguarnera, Mariano ^a  

^a CANNIZZARO HOSPITAL   (Italy)

Author keywords

Antihyperlipidaemic effects; HCV; Hepatic steatosis; Interferon alpha; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; CARNITINE; CHOLESTEROL; RIBAVIRIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; FATIGUE; FATTY LIVER; FEMALE; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN TISSUE; IRRITABILITY; LEUKOCYTE COUNT; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; CARNITINE; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RIBAVIRIN; VITAMIN B COMPLEX;

EID: 40749137434     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9983-1     Document Type: Article

References (47)

1. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Brechot C (1997) Hepatitis C Virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 94:1200-1205
2. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K (1997) Hepatitis C Virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78:1527-1531
3. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano Pl, Apolinario A, Larranaga E, Moreno-Otero R (2000) Characterization of pathogenetic and prognostic factors of non-alcoholic steatohepatitis associated with obesity. J Hepatol 33:716-724
4. Czaya AJ, Carpenter HA, Santrach PJ, Moore SB (1998) Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 29:198-206
5. Bach N, Thung SN, Shaffner F (1992) The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 15:572-577
6. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T (2000) Liver fibrosis in overweight patients. Gastroenterology 118:1117-1123
7. Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 30:1356-1362
8. Alter MJ, Kruszon-Moran D, Nainan OV, Mcquillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS (1999) The prevalence of hepatitis C virus infection in the United States 1988 through 1994. N Engl J Med 341:556-562
9. Lauer GM, Waker BD (2001) Hepatitis C Virus infection. N Engl J Med 345:41-52
10. Malaguarnera M, Giugno I, Trovato BA, Panebianco MP, Siciliano R, Ruello P (1995) Lipoprotein (A) concentration in patients with chronic active C before and after interferon treatment. Clin Ther 17:721-728
11. Malaguarnera M, Giugno I, Ruello P, Pistone G, Restuccia S, Trovato BA (1996) Effects of interferon on blood lipids. Clin Drug Invest 11:43-48
12. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM (2001) Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am J Gastroenterol 96:2468-2472
13. Rebouche CJ, Seim H (1998) Carnitine metabolism and its regulation in microorganisms and mammals. Ann Rev Nut 18:39-61
14. Romano M, Malaguarnera M, Vinci M, Batticani S, Consoli G, Navarria G (1996) Incidence and ultrasonographic patterns of hepatic steatosis in the elderly. Arch Gerontol Geriatr 5:313-316
15. Malaguarnera M, Restuccia N, Di Fazio I, Panebianco MP, Gulizia G, Giugno I (1999) Fish oil treatment of interferon-alpha-induced dyslipidemia: study in patients with chronic hepatitis C. Biodrugs 11:285-291
16. Malaguarnera M, Maugeri D, Saraceno B, Romano M, Neri S, Rapisarda R, Pistone G (2002) Effects of carnitine on biochemical responses in patients with chronic hepatitis C treated with interferon-Α. Clin Drug Invest 22:443-448
17. Malaguarnera I, Di Fazio S, Restuccia G, Pistone N, Restuccia BA (1998) Trovato efficacy of different schedules in the management of chronic hepatitis C with interferon-α. Ann Med 30:213-217
18. Alberti A, Benvegnu L (2003) Management of hepatitis C. J Hepatol 38:S104-118
19. Stuyver L, Wyseur A, Van Arnhem W, Hernandez F, Maertens G (1996) Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 34:2259-2266
20. Simmonds P, Alberti P, Halter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT (1994) A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321-1324
21. Knodell R, Ishack K, Black W (1981) Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435
22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474
23. Deufel T (1990) Determination of l-carnitine in biological fluids and tissues. J Clin Chem Clin Biochem 28:307-311
24. Malaguarnera L, Rosa MD, Zambito AM, Dell'ombra N, Marco RD, Malaguarnera M (2006) Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. Am J Gastroenterol 101(9):2060-2069 Epub 2006 Jul 18
25. Malaguarnera L, Di Rosa M, Zambito Am, Dell'ombra N, Nicoletti F, Malaguarnera M (2006) Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut 55(9):1313-1320 Epub 2006 Jul 6
26. Thomssen R, Bonk S, Propfee C, Heerman KH, Kochel HG, Uy A (1992) Association of hepatitis C virus in human sera with beta lipoprotein. Med Microbiol Immunol 181:293-300
27. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype. J Hepatol 33:106-115
28. Kumar D, Farrell GC, Fung C, George J (2002) Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 36:1266-1272
29. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis c patients and correlates with specific hcv genotype and visceral obesity. Hepatology 33:1358-1364
30. Shinohara E, Yamashita S, Kihara S, Hirano K, Ishigami M, Arai T, Nozaki S, Kameda-Takemura K, Kawata S, Matsuzawa Y (1997) Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 25:1502-1506
31. Dixon RM, Borden EC, Keim NL, Anderson S, Spennetta TL, Tormey DC, Shrago E (1984) Decreases in serum high-density lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons. Metabolism 33:400-404
32. Massaro ER, Borden EC, Hawkins MJ, Wiebe DA, Shrago E (1986) Effects of recombinant interferon-alpha 2 treatment upon lipid concentrations and lipoprotein composition. J Interferon Res 6:655-665
33. Maebashi M, Kawamura N, Sato M, Imamura A, Yoshinaga K (1978) Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia. Lancet 2:805-807
34. Khan L, Bamji MS (1979) Tissue carnitine deficiency due to dietary lysine deficiency: triglyceride accumulation and concomitant impairment in fatty acid oxidation. J Nutr 109:24-31
35. Richter V, Rassoul F, Schulz G, Sittner WD, Seim H, Loster H, Rotzsch W (1987) Carnitine and experimental carbohydrate-induced hyperlipoproteinemia. Arch Int Pharmacodyn Ther 290(1):138-144
36. Feng Y, Guo C, Wei J, Yang J, Ge Y, Gao L (2001) Necessity of carnitine supplementation in semistarved rats fed a high-fat diet. Nutrition 17(7-8):628-631
37. Malaguarnera M, Pistone G, Neri S, Romano M, Brogna A, Musumeci S (2004) Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment. Biodrugs 18:407-413
38. Famularo G, De Simone C (1995) A new era for carnitine? Immunol Today 16:211-213
39. Sougero C, Joo M, Chianese-Bulock KA, Nguyen DT, Tung K, Hahn V (2002) Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol 76:9345-9354
40. Lederblad G (1976) Plasma carnitine and body composition. Clin Chim Acta 67:207-212
41. Lysiak W, Lilly K, Dilisa F, Toth PP, Bieber LL (1988) Quantitation of the effect of l-carnitine on levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. J Biol Chem 263:1151-1155
42. Feng V, Suo CJ, Wei JV et al (2000) The impact of fat rich feeding on carnitine and lipid metabolism in half-starved rats. Chin J Clin Nutr 8:96-101
43. Lewis JA, Huq A, Najarro P (1996) Inhibition of mitochondrial function by interferon. J Biol Chem 271:13184-13190
44. Kraemer WJ, Volek JS, French DN, Rubin MR, Sharman MJ, Gomez AL, Ratamess NA, Newton RU, Jemiolo B, Craig BW, Hakkinen K (2003) The effects of l-carnitine l-tartrate supplementation on hormonal responses to resistance exercise and recovery. J Strength Cond Res 17(3):455-462. Pmid: 12930169
45. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, Mari M, Ardite E, Morales A (1997) Gsh transport in mitochondria: defense against tnf-induced oxidative stress and alcohol-induced defect. Am J Physiol 273(1 Pt 1):G7-17. Review. Pmid: 9252504
46. Quillet-Mary A, Jaffrezou JP, Mansat V, Bordier C, Naval J, Laurent G (1997) Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem 272(34):21388-21395. Pmid: 9261153
47. Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, Colina F, Arenas J, Solis-Herruzo JA (2003) Defective hepatic mitochondrial respiratory chain in patients with non-alcoholic steatohepatitis. Hepatology 38:999-1007